International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Cancer progression is a multi-step process that involves not only the uncontrolled growth of tumor cells but also the complex interactions between tumor cells and their surrounding microenvironment. Among the various factors influencing cancer progression, inflammation plays a crucial and often underestimated role. Tumor-associated inflammation (TAI) refers to the inflammatory response within the tumor microenvironment (TME), which includes immune cells, cytokines, growth factors, and extracellular matrix components. While inflammation is part of the body's natural defense mechanism, chronic and uncontrolled inflammation within the tumor can fuel cancer progression, promote metastasis, and enhance the ability of cancer cells to evade the immune system. This article explores how tumor-associated inflammation contributes to metastatic spread, tumor progression, and the implications of targeting inflammation for cancer therapy [1].

Description

The role of tumor-associated inflammation in metastasis and tumor progression

Inflammation as a driver of tumor initiation and progression: Tumor-associated inflammation is initiated when the tumor interacts with surrounding cells in the TME, including immune cells such as macrophages, neutrophils, and lymphocytes. Inflammatory mediators, including cytokines, chemokines, growth factors, and reactive oxygen species (ROS), are released by both tumor and stromal cells in response to stress signals. These mediators influence tumor behavior by promoting cellular changes that support tumor growth, survival, and resistance to therapy [2]. For instance, chronic inflammation can create a pro-tumorigenic environment by upregulating the expression of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF)-α, and interleukin-1β (IL-1β), all of which can drive tumor cell proliferation and survival.

Inflammatory cytokines like IL-6 activate the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, which promotes cellular proliferation, survival, and metastasis. Additionally, chronic inflammation is associated with DNA damage and genomic instability, which can lead to the initiation of cancerous transformations in nearby cells. This cascade of events provides a fertile ground for the development and progression of malignant tumors, with inflammation often being a driving force behind these processes [3].

Inflammation and metastasis: Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the leading cause of cancer-related deaths. Inflammation plays a central role in metastasis by promoting several key processes: invasion, migration, and the ability of tumor cells to colonize distant tissues. Tumor-associated inflammation contributes to these processes through the following mechanisms:

Activation of matrix metalloproteinases (MMPs): Tumor cells rely on the degradation of the extracellular matrix (ECM) to invade surrounding tissues and migrate to distant sites. Inflammatory cytokines and immune cells within the TME can upregulate the activity of MMPs, which break down the ECM, facilitating tumor cell invasion and migration [4].

Induction of epithelial-mesenchymal transition (EMT): Inflammation can induce EMT, a process in which epithelial tumor cells acquire mesenchymal characteristics, becoming more migratory and invasive. This transition is characterized by the loss of cell adhesion molecules (e.g., E-cadherin) and the gain of mesenchymal markers (e.g., N-cadherin, vimentin), allowing the tumor cells to detach from the primary tumor and invade surrounding tissues [5]. Key inflammatory mediators, such as IL-1β and TNF-α, play important roles in the activation of EMT pathways.

Immune cell recruitment and tumor invasion: Chronic inflammation promotes the recruitment of various immune cells to the TME, such as tumor-associated macrophages (TAMs), neutrophils, and myeloid-derived suppressor cells (MDSCs). These cells not only support tumor growth but also assist in the spread of cancer cells. TAMs, for example, can release growth factors and cytokines that stimulate angiogenesis, immune suppression, and ECM remodeling, all of which are necessary for tumor cells to invade neighboring tissues and metastasize [6].

Angiogenesis and vascular remodeling: Inflammation promotes the formation of new blood vessels (angiogenesis) within tumors, which is essential for tumor growth and metastasis. Inflammatory cytokines like VEGF (vascular endothelial growth factor) are produced by both tumor cells and infiltrating immune cells in response to chronic inflammation, leading to the development of a vascular network that nourishes the growing tumor and facilitates the spread of cancer cells into the bloodstream [7].

Chronic inflammation and immune evasion: A hallmark of metastatic cancer is its ability to evade detection and destruction by the host immune system. Tumor-associated inflammation not only enhances tumor cell proliferation and invasion but also promotes immune evasion. Inflammatory cytokines such as IL-10 and transforming growth factor-β (TGF-β) create an immunosuppressive environment within the TME by recruiting regulatory T cells (Tregs), MDSCs, and macrophages that suppress anti-tumor immunity. This immune tolerance allows the tumor to escape immune surveillance and continue growing and metastasizing without being targeted by the body’s natural defense mechanisms [8].

Furthermore, tumor-associated inflammation can also interfere with the effectiveness of cancer immunotherapies. Inflammatory mediators may alter the balance between immune-activating and immune-suppressive signals, reducing the ability of immune checkpoint inhibitors or adoptive T cell therapies to effectively target and destroy tumor cells [9].

Inflammation and the tumor microenvironment (TME) The TME is a dynamic and complex ecosystem that includes not only cancer cells but also stromal cells, immune cells, blood vessels, and extracellular matrix components. Tumor-associated inflammation reshapes the TME by promoting the recruitment of immune cells, the release of inflammatory cytokines, and the formation of new blood vessels. These changes facilitate tumor progression and metastatic spread [10]. The inflammatory response within the TME can lead to increased tissue remodeling, immune suppression, and resistance to conventional therapies, creating a challenging environment for effective cancer treatment.

Conclusion

Tumor-associated inflammation plays a pivotal role in both tumor progression and metastasis. Chronic inflammation within the tumor microenvironment fuels several processes that enable cancer cells to invade surrounding tissues, migrate to distant organs, and evade immune detection. By promoting DNA damage, EMT, immune suppression, angiogenesis, and ECM remodeling, inflammation significantly contributes to the aggressive nature of metastatic cancer. Understanding the intricate relationship between tumor-associated inflammation and cancer progression offers new opportunities for therapeutic intervention. Targeting inflammation through the use of anti-inflammatory agents, immune modulators, or combination therapies could improve cancer treatment outcomes by inhibiting metastatic spread and enhancing the efficacy of existing therapies. As research into the role of inflammation in cancer continues to evolve, strategies that address the inflammatory components of cancer could become key components in the fight against metastatic disease.

Acknowledgement

None

Conflict of Interest

None

1. Li Y, Wicha M, Schwartz S, Sun D (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 22: 799-806.

Indexed at, Google Scholar, Crossref

2. Suzuki R, Kang Y, Li X, Roife D, Zhang R, et al. (2014) Genistein potentiates the antitumor effect of 5-fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res 34: 4685-4692.

Indexed at, Google Scholar

3. Ma J, Cheng L, Liu H, Sarkar F, Xia J, et al. (2013) Genistein down-regulates mir-223 expression in pancreatic cancer cells. Current Drug Targets 14: 1150-1156.

Indexed at, Google Scholar, Crossref

4. El-Rayes B, Ali S, Ali I, Philip P, Abbruzzese J, et al. (2006) Potentiation of the effect of erlotinib by genistein in pancreatic cancer: The Role of AKT and nuclear factor-ĸB. Cancer Res 66: 10553-10559.

Indexed at, Google Scholar, Crossref

5. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, et al. (2005) Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 5: 9064-9072.

Indexed at, Google Scholar, Crossref

6. Han L, Zhang HW, Zhou WP, Chen GM, Guo KJ (2012) The effects of genistein on transforming growth factor-β1-induced invasion and metastasis in human pancreatic cancer cell line Panc-1 in vitro. Chin Med 125: 2032-2040.

Indexed at, Google Scholar, Crossref

7. El-Rayes B, Philip P, Sarkar F, Shields A, Wolff  R, et al. (2011) A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29: 694-699.

Indexed at, Google Scholar, Crossref

8. Bimonte S, Barbieri A, Palma G, Luciano A, Rea D, et al. (2013) Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. BioMed Res Intl 810423.

Indexed at, Google Scholar, Crossref

9. Ma J, Fang B, Zeng F, Pang H, Ma C, et al. (2014) Curcumin inhibits cell growth and invasion through up- regulation of miR-7 in pancreatic cancer cells. Toxicol Lett 31: 82-91.

Indexed at, Google Scholar, Crossref

10. Osterman CJ, Lynch J, Leaf P, Gonda A, Ferguson Bennit HR, et al. (2015) Curcumin modulates pancreatic adenocarcinoma cell-derived exosomal function. Plos One 10: e0132845.

Indexed at, Google Scholar, Crossref